Imagine a future where cancer treatment is not driven by toxic chemicals and invasive procedures, but instead uses the body's own immune system to fight and eliminate tumors. Thanks to groundbreaking research in cancer immunotherapy, that future may be closer than we think. IMMATICS is a leader in developing targeted therapies that enable the immune system to recognize and destroy cancer cells. Their innovative approaches, based on personalized TCR-T cell therapies and TCR Bispecifics, aim to develop cancer specific treatments with fewer side effects.
Innovative cancer immunotherapies
A cancer diagnosis often leads to a sense of hopelessness and fear of a long ordeal with chemotherapy and invasive treatments. The possibility of an alternative treatment that specifically targets the tumor would provide tremendous relief for patients and their families. Cancer immunotherapy could provide that opportunity. Instead of flooding the body with chemicals aimed at destroying any proliferating cells, including rapidly dividing cancer cells, immunotherapy uses the patient's immune system to recognize and attack cancer cells. This offers the potential for more precise treatments, resulting in reduced side effects and improved therapy outcomes. Potential side effects could include fever and cytokine release syndrome.
In their mission to improve the quality of life and therapeutic outcomes of cancer patients, Toni Weinschenk and Harpreet Singh founded IMMATICS, a company currently advancing two distinct therapeutic approaches: personalized T cell therapies and off-the-shelf TCR Bispecifics. These potential treatments are designed to empower the immune system to identify and destroy cancer cells by targeting certain peptides presented on the tumor’s surface. The cell therapy approach uses the patient’s own T cells that are genetically modified to express a T cell receptor (TCR) able to recognize these tumor-specific targets (TCR-T cell therapies), subsequently activating the T cell to destroy the tumor cell. TCR Bispecifics are antibody-like molecules that redirect and activate the patient’s T cells toward solid tumor cells.
A job for the body police
The immune system has preoccupied Harpreet Singh since childhood when his mom described the different cell types of the immune system as a "body police force”. He was fascinated by the idea of a police force patrolling his body during an infection. Singh has turned his childhood fascination into a career in oncology. Today, IMMATICS provides the immune system with a "mug shot" that helps the body’s police to specifically identify tumor cells and eliminate them. This approach has already shown promising results in clinical trials and could potentially transform cancer treatment.
A glimpse into the future
If successful, the IMMATICS approach could profoundly impact the future of cancer treatment. By harnessing the power of T cells to fight cancer, IMMATICS’ programs have the potential to provide effective, targeted, safe and non-invasive treatments for patients. If we can unlock the full potential of the immune system to fight cancer, it could be a major turning point in the fight against this devastating disease. With IMMATICS at the forefront of this effort, we can be optimistic about the future of cancer treatment and the lives it will save.
